EGEN-001 + carboplatin + docetaxel

EGEN-001 + carboplatin + docetaxel is an investigational combination regimen evaluated primarily for recurrent ovarian cancer. This combination consists of: - **EGEN-001**, a gene therapy formulated as a plasmid encoding human interleukin-12 (IL-12) and delivered intraperitoneally using a synthetic DNA delivery system (polyethyleneglycol-polyethyleneimine-cholesterol, PPC). EGEN-001 acts by stimulating an immune response against tumor cells, promoting natural killer cell activation, IFN-γ secretion, a T-helper 1 immune shift, and inhibiting neovascularization. - **Carboplatin**, a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis. - **Docetaxel**, a taxane chemotherapeutic that stabilizes microtubules and causes cell cycle arrest. The regimen is typically used with EGEN-001 given via intraperitoneal infusion, in combination with intravenous carboplatin and docetaxel at standard oncology doses for ovarian cancer. Preclinical and early-phase clinical data support the immune-mediated and cytotoxic synergy for this combination in platinum-sensitive and recurrent ovarian cancer[1][3][5]. In phase I studies, the combination showed feasibility, manageable toxicity, and signs of antitumor activity; most adverse events were low grade, including fever and abdominal pain, but some patients experienced anemia and peritonitis. This regimen has not been approved for any indication.